Hoth Therapeutics, Inc. to Begin Pilot Study at Massachusetts General Hospital Vaccine and Immunotherapy Center

Monday, March 4, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Study will aim to determine the efficacy of the BioLexa Platform in the context of chronic diabetic ulcers, with and without substantial bacterial burden.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store